CN106659762A - Nmdar调节化合物的组合 - Google Patents

Nmdar调节化合物的组合 Download PDF

Info

Publication number
CN106659762A
CN106659762A CN201580031430.2A CN201580031430A CN106659762A CN 106659762 A CN106659762 A CN 106659762A CN 201580031430 A CN201580031430 A CN 201580031430A CN 106659762 A CN106659762 A CN 106659762A
Authority
CN
China
Prior art keywords
nmdar antagonist
glyx
nmdar
group
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580031430.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·莫斯卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORTHWEST UNIVERSITY
Original Assignee
NORTHWEST UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORTHWEST UNIVERSITY filed Critical NORTHWEST UNIVERSITY
Publication of CN106659762A publication Critical patent/CN106659762A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580031430.2A 2014-05-06 2015-05-06 Nmdar调节化合物的组合 Pending CN106659762A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989183P 2014-05-06 2014-05-06
US61/989,183 2014-05-06
PCT/US2015/029477 WO2015171770A1 (en) 2014-05-06 2015-05-06 Combinations of nmdar modulating compounds

Publications (1)

Publication Number Publication Date
CN106659762A true CN106659762A (zh) 2017-05-10

Family

ID=54392956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580031430.2A Pending CN106659762A (zh) 2014-05-06 2015-05-06 Nmdar调节化合物的组合

Country Status (11)

Country Link
US (1) US20170072005A1 (https=)
EP (1) EP3139943A4 (https=)
JP (3) JP2017514871A (https=)
KR (2) KR20170013890A (https=)
CN (1) CN106659762A (https=)
AU (1) AU2015256075B2 (https=)
BR (1) BR112016025910A8 (https=)
CA (1) CA2947976A1 (https=)
MX (1) MX2016014581A (https=)
RU (1) RU2721948C2 (https=)
WO (1) WO2015171770A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107550907A (zh) * 2017-08-29 2018-01-09 昆明医科大学 治疗精神分裂症的药物及验证药物的动物模型构建方法
WO2020088270A1 (zh) * 2018-10-29 2020-05-07 中国药科大学 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用
CN111670041A (zh) * 2017-12-05 2020-09-15 诺雷克斯股份有限公司 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合
CN113234036A (zh) * 2021-05-12 2021-08-10 中国科学院上海有机化学研究所 Nmda受体拮抗剂及其用途
CN119174765A (zh) * 2024-09-04 2024-12-24 复旦大学附属中山医院 Gsdme蛋白的小分子抑制剂在肿瘤及其免疫治疗中的作用
WO2025124571A1 (zh) * 2023-12-14 2025-06-19 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017107558A (ru) 2014-09-15 2018-10-18 Руджен Холдингс (Кайман) Лимитед Производные пирролопиримидина в качестве антагонистов nmda-рецептора nr2b
WO2016049048A1 (en) * 2014-09-22 2016-03-31 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用
KR102613179B1 (ko) 2015-06-01 2023-12-14 뤼겐 홀딩스 (케이맨) 리미티드 Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물
CN108601814A (zh) * 2015-10-16 2018-09-28 西北大学 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合
AU2016337507B2 (en) * 2015-10-16 2019-09-19 Impact Biosciences Corp. Methods and compositions for treating traumatic brain injury
JP6967532B2 (ja) * 2016-05-25 2021-11-17 ナショナル ヘルス リサーチ インスティテューツNational Health Research Institutes 付加的抗うつ剤組成物及びその使用方法
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
CN110343050B (zh) 2018-04-04 2021-09-24 上海键合医药科技有限公司 芳香类化合物及其制备方法和用途
CN113557028A (zh) * 2019-01-11 2021-10-26 诺雷克斯股份有限公司 雷帕替奈的盐和晶型
EP3923938B1 (en) * 2019-02-14 2025-04-16 Seyltx, Inc. Ifenprodil or radiprodil for treating idiopathic pulmonary fibrosis
EP4051276B1 (en) 2019-10-28 2025-08-06 Seyltx, Inc. Use of glutamate 2b receptor antagonists and sigma receptor agonsists as antitussives
KR20230056971A (ko) * 2021-10-21 2023-04-28 삼육대학교산학협력단 신규 케타민 유도체를 포함하는 우울증 예방 또는 치료용 약학적 조성물
WO2024059713A2 (en) 2022-09-14 2024-03-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions of iboga alkaloids and methods of treatment
WO2025065271A1 (en) * 2023-09-26 2025-04-03 Liangzhu Laboratory Methods and devices for treating depression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
US20130310323A1 (en) * 2009-10-05 2013-11-21 Northwestern University Methods of Treating Depression and Other Related Diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
EP2260844A1 (en) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
GB0523998D0 (en) * 2005-11-25 2006-01-04 Merck Sharp & Dohme Therapeutic agents
US8071807B2 (en) * 2008-07-03 2011-12-06 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
EP2381941A4 (en) * 2008-12-29 2012-08-01 Univ Vanderbilt 3.1.0 BICYCLIC GLYTI INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2992877A1 (en) * 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
US20130310323A1 (en) * 2009-10-05 2013-11-21 Northwestern University Methods of Treating Depression and Other Related Diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIAO-LEI ZHANG ET,AL: "A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral–CA1 synapses in hippocampus", 《NEUROPHARMACOLOGY》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107550907A (zh) * 2017-08-29 2018-01-09 昆明医科大学 治疗精神分裂症的药物及验证药物的动物模型构建方法
CN111670041A (zh) * 2017-12-05 2020-09-15 诺雷克斯股份有限公司 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合
WO2020088270A1 (zh) * 2018-10-29 2020-05-07 中国药科大学 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用
CN113234036A (zh) * 2021-05-12 2021-08-10 中国科学院上海有机化学研究所 Nmda受体拮抗剂及其用途
WO2022237849A1 (zh) * 2021-05-12 2022-11-17 中国科学院上海有机化学研究所 Nmda受体拮抗剂及其用途
WO2025124571A1 (zh) * 2023-12-14 2025-06-19 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途
CN119174765A (zh) * 2024-09-04 2024-12-24 复旦大学附属中山医院 Gsdme蛋白的小分子抑制剂在肿瘤及其免疫治疗中的作用

Also Published As

Publication number Publication date
JP2020138973A (ja) 2020-09-03
US20170072005A1 (en) 2017-03-16
AU2015256075A1 (en) 2016-11-24
JP2022159322A (ja) 2022-10-17
CA2947976A1 (en) 2015-11-12
RU2721948C2 (ru) 2020-05-25
BR112016025910A2 (pt) 2017-08-15
KR20170013890A (ko) 2017-02-07
JP2017514871A (ja) 2017-06-08
EP3139943A1 (en) 2017-03-15
EP3139943A4 (en) 2018-07-18
KR20220102662A (ko) 2022-07-20
MX2016014581A (es) 2018-02-16
WO2015171770A1 (en) 2015-11-12
RU2016146714A (ru) 2018-06-06
RU2016146714A3 (https=) 2018-10-08
AU2015256075B2 (en) 2021-02-25
BR112016025910A8 (pt) 2021-07-13

Similar Documents

Publication Publication Date Title
CN106659762A (zh) Nmdar调节化合物的组合
JP5883399B2 (ja) ｍＧｌｕＲ４アロステリック増強剤としてのピラゾロピリジン、ピラゾロピラジン、ピラゾロピリミジン、ピラゾロチオフェンおよびピラゾロチアゾール化合物、組成物、および神経機能不全を治療する方法
US11578072B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
CN111065390B (zh) Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途
VanderZwaag et al. The missing piece? A case for microglia’s prominent role in the therapeutic action of anesthetics, ketamine, and psychedelics
CA3183413A1 (en) Combination treatment of liver disorders
US6369052B1 (en) Combination of huperzine and nicotinic compounds as a neuroprotective agent
JP2020516591A (ja) Ｍｏｒアゴニストおよびｋｏｒアゴニストを含有する医薬組成物、およびその用途
CN108601814A (zh) 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合
KR20080093453A (ko) 4-아실아미노피리딘 유도체 매개된 신경조직발생
JP2023133571A (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
US9023788B2 (en) Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders
KR20140027939A (ko) 지양제
CN111406050B (zh) 吲哚胺2,3-双加氧酶抑制剂及其用途
CN105209445B (zh) 治疗运动障碍和相关病症的方法
JP2017524721A (ja) Ｎｍｄａ調節剤を使用するうつ病の治療方法
AU2022246090B2 (en) Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents
CN111825698A (zh) 腺苷受体拮抗剂
AU2007321218A1 (en) Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents
HK1237649A1 (zh) Nmdar调节化合物的组合
US9265774B2 (en) Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
EP4168441A1 (en) Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase system
JP2019509321A (ja) 疼痛を処置するための組み合わせ
CN106132966A (zh) 用于治疗智力残疾的mglu2/3拮抗剂
RU2802972C2 (ru) Фармацевтическая комбинация атипичного антипсихотика и модулятора nmda для лечения шизофрении, биполярного расстройства, когнитивного нарушения и клинической депрессии

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1237649

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170510

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1237649

Country of ref document: HK